What does Melanotan II do? Benefits and evidence
An unapproved tanning peptide with small human trials and reports of serious harm.
Also called: Melanotan-2, MT-II, MT2, MT-2.
Melanocortin agonists · Nonselective melanocortin receptor agonist.
Melanotan II is an unapproved tanning peptide, sometimes used for libido. Individual reports describe changing moles, melanoma, prolonged erections and severe illness, but cannot prove it caused them or measure risk. Three small experiments enrolled 23 men. Online injections and nasal sprays have uncertain contents and strength.
- People report darker skin, often while using sunbeds or sunlight; tanning is not an approved use. (Reported by users)
- In two small trials of 10 men each, injections caused erections and more desire, though nausea was common. (Studied in a trial)
- In the first small study in people, injections darkened the skin and caused erections. (Studied in a trial)
Uses in the sources
- Community users report darker skin, often with sunbeds or sunlight. Cosmetic tanning is not an approved indication. (Reported by users) (source)
- Two small trials of 10 men each found erections after injection. They do not establish routine treatment or long-term safety. (Studied in a trial) (source)
- A 2026 phase 2 registration proposes use with NB-UVB for vitiligo. No results or usable dose schedule are posted. (Studied in a trial) (source)
Related to Melanotan II
- Bremelanotide: An as-needed injection for low libido before menopause; nausea is common.
- Melanotan I / Afamelanotide: The molecule in an approved EPP implant; online tanning powder is a different formulation.
- Setmelanotide: A daily injection approved for specific genetic obesity and acquired hypothalamic obesity.
- Retatrutide: An experimental weekly injection with phase 3 weight-loss results.
- GHK-Cu: A copper-binding skin peptide with small topical studies and untested systemic injections.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, US Food and Drug Administration · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Compounding and the FDA: Questions and Answers, FDA · FDA · 2026
- Meeting of the Pharmacy Compounding Advisory Committee, FDA · 2026
- Melanotan II tanning peptide products found to be inconsistently dosed, 2026
- Scenesse, 2026
- Scenesse, INN-afamelanotide, 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Don’t risk using tanning products containing melanotan, 2025
- Written questions and answers - Written questions, answers and statements - UK Parliament, 2025
- Priapism (painful erections) - NHS, NHS · 2023
- Notice of Opportunity for Hearing (NOOH) Manookian, Edward 8/5/16, 2016
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.